Advances in Research and Treatment for Alzheimer's Disease
Alzheimer's disease (AD), is the most common form of dementia. There is no cure for the disease, which worsens as it progresses, and eventually leads to death. The cause and progression of Alzheimer's disease are not well understood. Research indicates that the disease is associated with plaques and tangles in the brain. Current treatments only help with the symptoms of the disease. There are no available treatments that stop or reverse the progression of the disease. As of 2012, more than 1000 clinical trials have been or are being conducted to find ways to treat the disease, but it is unknown if any of the tested treatments will work. Because AD cannot be cured and is degenerative, the sufferer relies on others for assistance. The role of the main caregiver is often taken by the spouse or a close relative. Alzheimer's disease is known for placing a great burden on caregivers; the pressures can be wide-ranging, involving social, psychological, physical, and economic elements of the caregiver's life. In developed countries, AD is one of the most costly diseases to society. Research is the only hope to present and future patients and families suffering from this devastating disorder. This book compiles some of the most interesting articles on Alzheimer's disease published by PLoS journals lately: from epidemiology and prevention to management and treatment.
What people are saying - Write a review
We haven't found any reviews in the usual places.
activity Ageing Study Alzheimer disease Alzheimer’s disease amyloid pathology amyloid precursor protein analysis animals antibody assessment associated baseline bradycardia brain Brayne carer cells ChEIs cholinesterase inhibitors clearance clinical trials cognitive decline cohort continue treatment Council Cognitive Function criteria demented dementia at death diagnosis difference donepezil drugs effects efficacy estimated mean ex vivo gene fibroblasts Figure Function and Ageing galantamine Geriatr graft hippocampus hospitalization for bradycardia included individuals interventions interview levels Lewy bodies LMICs Median IQR Medical Research Council memory mental Meta-analysis mild cognitive impairment MMSE mo of age Moderate mouse model MRC CFAS neprilysin Neurol neuroleptics neuropathology Neurosci outcome Parkinson disease participants patients peptide placebo placebo groups population prevalence of dementia primary protease Psychiatry randomised RCTs reduce Research Council Cognitive rivastigmine score severe cognitive impairment significant sNEP therapy transgene suppression transgenic transgenic mice Tukey post-hoc test untreated mice vascular dementia vector